NovoCure (NVCR): Evaluating Valuation as METIS Phase 3 Brain Metastases Results Reach Industry Conference Milestone

NovoCure (NVCR) just announced that final results from its pivotal Phase 3 METIS trial for Tumor Treating Fields therapy in brain metastases from non-small cell lung cancer will be presented at a major industry conference and published in a top journal.

See our latest analysis for NovoCure.

While NovoCure’s latest trial update sparked interest, the company’s momentum has been mixed. After a challenging start to the year, share price rebounded with an 11% gain over the past month. However, longer-term total shareholder return remains deeply negative at -14% for one year and -81% over three years.

If you’re curious about which other healthcare stocks are showing resilience and innovation, check out the full lineup with our See the full list for free.

With shares trading well below analyst targets, but negative returns lingering over several years, the question weighs on investors: is NovoCure now undervalued, or does the current price already reflect all future growth prospects?

Most Popular Narrative: 50% Undervalued

NovoCure’s most popular narrative sets its fair value far above the recent closing price, reflecting high expectations despite recent setbacks. This creates an outlook based on significant business model expansion ahead.

Validation of TTFields therapy in multiple new indications, such as pancreatic cancer (PANOVA-3) and brain metastases from non-small cell lung cancer (METIS), positions NovoCure for potential regulatory approvals and large market expansion beginning in 2026. This could drive topline revenue growth as global cancer incidence rises in the aging population.

Read the complete narrative.

Curious what bold financial forecasts underpin this massive upside? The secret is in aggressive revenue growth assumptions and a profit turnaround that could flip the script for NovoCure. Find out what ambitious targets are built into this valuation and what it takes for the company to earn its place among oncology leaders.

Result: Fair Value of $27.19 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, slower-than-expected U.S. prescription growth and persistent reimbursement challenges could undermine confidence in NovoCure’s long-term revenue outlook.

Find out about the key risks to this NovoCure narrative.

Build Your Own NovoCure Narrative

If you’re not convinced by the consensus or want to follow your own reasoning, dive into the data and shape your own perspective in just minutes with our Do it your way

A great starting point for your NovoCure research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Why limit your strategy to just one company? Take charge of your portfolio by tapping into these unique opportunities handpicked for strong momentum and future growth.

• Uncover undervalued gems poised for a rebound by using our these 892 undervalued stocks based on cash flows to spot stocks primed for strong performance based on cash flow fundamentals.
• Start earning while you wait with these 19 dividend stocks with yields > 3% featuring attractive yields above 3% and a track record of reliable payouts.
• Seize your early advantage in the booming artificial intelligence sector by checking out these 24 AI penny stocks already capturing the biggest AI trends in the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com